$0.88
+0.01 (+1.60%)
Open$0.88
Previous Close$0.86
Day High$0.91
Day Low$0.86
52W High$5.75
52W Low$0.57
Volume—
Avg Volume175.8K
Market Cap30.62M
P/E Ratio—
EPS$-1.41
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,714.0% upside
Current
$0.88
$0.88
Target
$15.90
$15.90
$11.92
$15.90 avg
$19.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.64M | 3.84M | 3.77M |
| Net Income | 720.4K | 800.4K | 930.4K |
| Profit Margin | 19.8% | 20.8% | 24.7% |
| EBITDA | 1.38M | 1.54M | 1.32M |
| Free Cash Flow | 559.4K | 545.0K | 561.2K |
| Rev Growth | +15.7% | +20.7% | +9.8% |
| Debt/Equity | 0.34 | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |